About Titan Pharmaceuticals, Inc. - Common Stock (TTNP)
Titan Pharma is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for the treatment of chronic conditions and unmet medical needs. The company is particularly known for its advanced drug delivery systems, which aim to improve the efficacy and convenience of administering medications. By leveraging cutting-edge technology, Titan Pharma develops proprietary implants and other formulations designed to provide long-lasting therapeutic effects, particularly in the fields of addiction treatment and pain management. The company's commitment to research and development underscores its goal of creating impactful solutions that enhance patient outcomes and transform healthcare. Read More
New York, NY – October 3, 2025 – Black Titan Corporation (NYSE: BTTC) witnessed a dramatic 58.30% decline in its stock price today, a sharp reversal after an astonishing nearly 300% surge just yesterday. This significant plunge, which saw the stock trading around $10.02, down from a previous close of
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Titan Pharmaceuticals, Inc. (the “Company”) (NasdaqCM: TTNP) and KE Sdn. Bhd. Under the terms of the proposed transaction, shareholders of Titan are expected to own approximately 13.3% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to the Company’s shareholders.
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
NEW YORK, July 26, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
BALA CYNWYD, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
NEW YORK, Aug. 24, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Titan Pharmaceuticals, Inc. (the “Company”) (NasdaqCM: TTNP) and KE Sdn. Bhd. Under the terms of the proposed transaction, shareholders of Titan are expected to own approximately 13.3% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to the Company’s shareholders.
